2.26
+0.03(+1.35%)
Currency In USD
| Previous Close | 2.23 |
| Open | 2.3 |
| Day High | 2.31 |
| Day Low | 2.08 |
| 52-Week High | 5.31 |
| 52-Week Low | 1.84 |
| Volume | 2.62M |
| Average Volume | 520,559 |
| Market Cap | 78.39M |
| PE | -1.67 |
| EPS | -1.35 |
| Moving Average 50 Days | 3 |
| Moving Average 200 Days | 3.58 |
| Change | 0.03 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $0.44 as of July 01, 2025 at a share price of $2.26. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $282.5 as of July 01, 2025 at a share price of $2.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
GlobeNewswire Inc.
3 hours ago
SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
GlobeNewswire Inc.
Jun 27, 2025 3:43 AM GMT
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat
Achieve Life Sciences Announces Proposed Underwritten Public Offering
GlobeNewswire Inc.
Jun 26, 2025 8:03 PM GMT
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat